Macquarie University   Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3
Founded: Sydney Australia (1964)

Organization Overview

First Clinical Trial
2013
NCT01711125
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2024

Timeline

NOW
  • Now

Alternative names

Macquarie University | Macquarie University, Australia | Macquarie University, Sydney

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Alcoholism (Phase 3)

Amyotrophic Lateral Sclerosis (Phase 3)

Fatigue (Phase 2)

Liver Diseases (Phase 3)

Liver Diseases, Alcoholic (Phase 3)

Motor Neuron Disease (Phase 3)

Prostatic Neoplasms (Phase 2)

Sclerosis (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 14
  • # of Trial APIs: 13